Commonwealth Retirement Investments LLC Has $225,000 Position in Gilead Sciences, Inc. $GILD

Commonwealth Retirement Investments LLC lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 91.8% in the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 2,033 shares of the biopharmaceutical company’s stock after selling 22,724 shares during the quarter. Commonwealth Retirement Investments LLC’s holdings in Gilead Sciences were worth $225,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. GoalVest Advisory LLC increased its position in Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the period. Activest Wealth Management increased its position in Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares during the period. Harbor Asset Planning Inc. acquired a new stake in Gilead Sciences during the 2nd quarter valued at approximately $27,000. Putney Financial Group LLC increased its position in Gilead Sciences by 53.4% during the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the period. Finally, Colonial Trust Advisors increased its position in Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 213 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $123.00 on Wednesday. Gilead Sciences, Inc. has a 52 week low of $86.08 and a 52 week high of $124.61. The firm has a 50 day moving average of $115.98 and a 200-day moving average of $111.92. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The company has a market cap of $152.62 billion, a price-to-earnings ratio of 24.50, a price-to-earnings-growth ratio of 0.81 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same quarter last year, the firm posted $2.02 EPS. Gilead Sciences’s revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be given a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.6%. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Insider Activity at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total value of $354,240.00. Following the completion of the sale, the insider owned 110,193 shares of the company’s stock, valued at approximately $13,011,589.44. This trade represents a 2.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the sale, the chief executive officer directly owned 581,203 shares of the company’s stock, valued at approximately $69,389,826.17. The trade was a 1.69% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 71,500 shares of company stock valued at $8,336,040. 0.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on GILD. Cantor Fitzgerald reissued an “overweight” rating and set a $135.00 target price on shares of Gilead Sciences in a research report on Friday, October 31st. BMO Capital Markets increased their target price on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an “outperform” rating in a research report on Monday, October 20th. Wells Fargo & Company increased their target price on shares of Gilead Sciences from $140.00 to $145.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. The Goldman Sachs Group raised their price objective on shares of Gilead Sciences from $108.00 to $110.00 and gave the stock a “neutral” rating in a research report on Friday, October 31st. Finally, UBS Group raised their price objective on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $125.08.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.